Schonfeld Strategic Advisors’s UroGen Pharma URGN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Sell	32,459 -125,652	-79%	-$3.41M	﹤0.01%	1374
2026 Q1	$2.84M	Buy	+158,111	New	+$3.17M	0.02%	678
2025 Q4	–	Sell	-297,851	Closed	-$5.94M	–	2607
2025 Q3	$5.94M	Buy	297,851 +79,351	+36%	+$1.42M	0.03%	530
2025 Q2	$2.99M	Buy	218,500 +148,711	+213%	+$1.43M	0.02%	783
2025 Q1	$772K	Buy	69,789 +1,689	+2%	+$18K	﹤0.01%	1391
2024 Q4	$725K	Sell	68,100 -56,200	-45%	-$673K	﹤0.01%	1258
2024 Q3	$1.58M	Sell	124,300 -124,099	-50%	-$1.84M	0.01%	992
2024 Q2	$4.17M	Buy	248,399 +144,299	+139%	+$2.05M	0.03%	615
2024 Q1	$1.56M	Sell	104,100 -27,800	-21%	-$454K	0.01%	1069
2023 Q4	$1.98M	Buy	131,900 +1,700	+1%	+$22.1K	0.01%	802
2023 Q3	$1.82M	Buy	+130,200	New	+$2.09M	0.01%	857

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Schonfeld Strategic Advisors's URGN Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its UroGen Pharma (URGN) stake by 79% in Q2 2026, selling an estimated $3.41M and leaving 32,459 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Schonfeld Strategic Advisors first reported a position in URGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $5.94M in Q3 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Schonfeld Strategic Advisors held 32,459 shares of UroGen Pharma worth $1.19M as of Q2 2026.
Schonfeld Strategic Advisors sold 125,652 UroGen Pharma shares in Q2 2026, an estimated $3.41M.
UroGen Pharma made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1374 holding.
Schonfeld Strategic Advisors first reported a position in UroGen Pharma in Q3 2023 and has held it in 11 quarters since.
Schonfeld Strategic Advisors's UroGen Pharma position peaked at $5.94M in Q3 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.